This document is an excerpt from the EUR-Lex website
Document 52025XC02785
Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 April 2025 to 30 April 2025 (Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council or Article 5 of Regulation (EU) 2019/6 of the European Parliament and of the Council)
Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 April 2025 to 30 April 2025 (Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council or Article 5 of Regulation (EU) 2019/6 of the European Parliament and of the Council)
Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 April 2025 to 30 April 2025 (Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council or Article 5 of Regulation (EU) 2019/6 of the European Parliament and of the Council)
PUB/2025/519
OJ C, C/2025/2785, 28.5.2025, ELI: http://data.europa.eu/eli/C/2025/2785/oj (BG, ES, CS, DA, DE, ET, EL, EN, FR, GA, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
|
Official Journal |
EN C series |
|
C/2025/2785 |
28.5.2025 |
Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 April 2025 to 30 April 2025
(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council (1) or Article 5 of Regulation (EU) 2019/6 of the European Parliament and of the Council (2) )
(C/2025/2785)
—
Issuing of a marketing authorisation (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted|
Date of the decision |
Name of the medicinal product |
INN (International Non-Proprietary Name) |
Holder of the marketing authorisation |
Number of the entry in the Community Register |
Pharmaceutical form |
ATC code (Anatomical Therapeutic Chemical Code) |
Date of notification |
||
|
4.4.2025 |
Datroway |
Datopotamab deruxtecan |
|
EU/1/25/1915 |
Powder for concentrate for solution for infusion |
L01FX35 |
8.4.2025 |
||
|
4.4.2025 |
PAVBLU |
Aflibercept |
|
EU/1/25/1909 |
Solution for injection in a pre-filled syringe Solution for injection in a vial |
S01LA05 |
7.4.2025 |
||
|
15.4.2025 |
LEQEMBI |
Lecanemab |
|
EU/1/24/1891 |
Concentrate for solution for infusion |
N06DX04 |
15.4.2025 |
||
|
23.4.2025 |
Filspari |
Sparsentan |
|
EU/1/23/1788 |
Film-coated tablet |
C09XX01 |
25.4.2025 |
||
|
23.4.2025 |
LYNOZYFIC |
linvoseltamab |
|
EU/1/25/1917 |
Concentrate for solution for infusion |
L01FX |
25.4.2025 |
||
|
23.4.2025 |
Vyjuvek |
Beremagene geperpavec |
|
EU/1/25/1918 |
Suspension and gel for gel |
D03AX16 |
24.4.2025 |
||
|
25.4.2025 |
Trabectedin Accord |
trabectedin |
|
EU/1/24/1902 |
Powder for concentrate for solution for infusion |
L01CX01 |
29.4.2025 |
—
Modification of a marketing authorisation (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted|
Date of the decision |
Name of the medicinal product |
Holder of the marketing authorisation |
Number of the entry in the Community Register |
Date of notification |
||
|
3.4.2025 |
Ketoconazole Esteve |
|
EU/1/14/965 |
4.4.2025 |
||
|
4.4.2025 |
Briumvi |
|
EU/1/23/1730 |
8.4.2025 |
||
|
4.4.2025 |
Capecitabine Accord |
|
EU/1/12/762 |
7.4.2025 |
||
|
4.4.2025 |
Darzalex |
|
EU/1/16/1101 |
7.4.2025 |
||
|
4.4.2025 |
Ebvallo |
|
EU/1/22/1700 |
7.4.2025 |
||
|
4.4.2025 |
Ecansya |
|
EU/1/12/763 |
7.4.2025 |
||
|
4.4.2025 |
Fingolimod Accord |
|
EU/1/20/1450 |
7.4.2025 |
||
|
4.4.2025 |
Finlee |
|
EU/1/23/1767 |
7.4.2025 |
||
|
4.4.2025 |
Kaftrio |
|
EU/1/20/1468 |
7.4.2025 |
||
|
4.4.2025 |
Kalydeco |
|
EU/1/12/782 |
7.4.2025 |
||
|
4.4.2025 |
Ketoconazole Esteve |
|
EU/1/14/965 |
8.4.2025 |
||
|
4.4.2025 |
KEYTRUDA |
|
EU/1/15/1024 |
7.4.2025 |
||
|
4.4.2025 |
Lenvima |
|
EU/1/15/1002 |
7.4.2025 |
||
|
4.4.2025 |
Lysodren |
|
EU/1/04/273 |
8.4.2025 |
||
|
4.4.2025 |
Ondexxya |
|
EU/1/18/1345 |
7.4.2025 |
||
|
4.4.2025 |
RINVOQ |
|
EU/1/19/1404 |
7.4.2025 |
||
|
4.4.2025 |
Rybrevant |
|
EU/1/21/1594 |
8.4.2025 |
||
|
4.4.2025 |
Tafinlar |
|
EU/1/13/865 |
7.4.2025 |
||
|
4.4.2025 |
Waylivra |
|
EU/1/19/1360 |
7.4.2025 |
||
|
4.4.2025 |
Xenleta |
|
EU/1/20/1457 |
7.4.2025 |
||
|
4.4.2025 |
Zercepac |
|
EU/1/20/1456 |
7.4.2025 |
||
|
10.4.2025 |
Columvi |
|
EU/1/23/1742 |
11.4.2025 |
||
|
10.4.2025 |
Flucelvax |
|
EU/1/24/1879 |
11.4.2025 |
||
|
14.4.2025 |
Arsenic trioxide Mylan |
|
EU/1/20/1427 |
15.4.2025 |
||
|
14.4.2025 |
Livogiva |
|
EU/1/20/1462 |
15.4.2025 |
||
|
14.4.2025 |
Lunsumio |
|
EU/1/22/1649 |
15.4.2025 |
||
|
14.4.2025 |
Oyavas |
|
EU/1/20/1510 |
16.4.2025 |
||
|
14.4.2025 |
Xenleta |
|
EU/1/20/1457 |
17.4.2025 |
||
|
16.4.2025 |
Ovaleap |
|
EU/1/13/871 |
22.4.2025 |
||
|
16.4.2025 |
Sprycel |
|
EU/1/06/363 |
22.4.2025 |
||
|
16.4.2025 |
Targretin |
|
EU/1/01/178 |
22.4.2025 |
||
|
16.4.2025 |
Vafseo |
|
EU/1/23/1725 |
23.4.2025 |
||
|
17.4.2025 |
Alymsys |
|
EU/1/20/1509 |
22.4.2025 |
||
|
17.4.2025 |
Enbrel |
|
EU/1/99/126 |
23.4.2025 |
||
|
17.4.2025 |
Glivec |
|
EU/1/01/198 |
24.4.2025 |
||
|
23.4.2025 |
Ahzantive |
|
EU/1/24/1888 |
24.4.2025 |
||
|
23.4.2025 |
Apixaban Accord |
|
EU/1/20/1458 |
24.4.2025 |
||
|
23.4.2025 |
AQUMELDI |
|
EU/1/23/1717 |
24.4.2025 |
||
|
23.4.2025 |
Insulin aspart Sanofi |
|
EU/1/20/1447 |
28.4.2025 |
||
|
23.4.2025 |
Lutathera |
|
EU/1/17/1226 |
28.4.2025 |
||
|
23.4.2025 |
Lyrica |
|
EU/1/04/279 |
25.4.2025 |
||
|
23.4.2025 |
MAVENCLAD |
|
EU/1/17/1212 |
24.4.2025 |
||
|
23.4.2025 |
Neparvis |
|
EU/1/16/1103 |
28.4.2025 |
||
|
23.4.2025 |
OPDIVO |
|
EU/1/15/1014 |
24.4.2025 |
||
|
23.4.2025 |
Retsevmo |
|
EU/1/20/1527 |
25.4.2025 |
||
|
23.4.2025 |
Spikevax |
|
EU/1/20/1507 |
25.4.2025 |
||
|
23.4.2025 |
TOBI Podhaler |
|
EU/1/10/652 |
25.4.2025 |
||
|
23.4.2025 |
Tremfya |
|
EU/1/17/1234 |
24.4.2025 |
||
|
23.4.2025 |
Upstaza |
|
EU/1/22/1653 |
28.4.2025 |
||
|
25.4.2025 |
Axumin |
|
EU/1/17/1186 |
29.4.2025 |
||
|
25.4.2025 |
Cufence |
|
EU/1/19/1365 |
30.4.2025 |
||
|
25.4.2025 |
Cuprior |
|
EU/1/17/1199 |
28.4.2025 |
||
|
25.4.2025 |
DaTSCAN |
|
EU/1/00/135 |
28.4.2025 |
||
|
25.4.2025 |
Deltyba |
|
EU/1/13/875 |
30.4.2025 |
||
|
25.4.2025 |
Fabrazyme |
|
EU/1/01/188 |
29.4.2025 |
||
|
25.4.2025 |
IBRANCE |
|
EU/1/16/1147 |
28.4.2025 |
||
|
25.4.2025 |
Intuniv |
|
EU/1/15/1040 |
28.4.2025 |
||
|
25.4.2025 |
Koselugo |
|
EU/1/21/1552 |
28.4.2025 |
||
|
25.4.2025 |
Mixtard |
|
EU/1/02/231 |
29.4.2025 |
||
|
25.4.2025 |
Orkambi |
|
EU/1/15/1059 |
28.4.2025 |
||
|
25.4.2025 |
PREVYMIS |
|
EU/1/17/1245 |
29.4.2025 |
||
|
25.4.2025 |
Ryzneuta |
|
EU/1/24/1793 |
2.5.2025 |
||
|
25.4.2025 |
SCENESSE |
|
EU/1/14/969 |
30.4.2025 |
||
|
25.4.2025 |
SOTYKTU |
|
EU/1/23/1718 |
30.4.2025 |
||
|
25.4.2025 |
VANFLYTA |
|
EU/1/23/1768 |
29.4.2025 |
—
Withdrawal of a marketing authorisation (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council)|
Date of the decision |
Name of the medicinal product |
Holder of the marketing authorisation |
Number of the entry in the Community Register |
Date of notification |
||
|
10.4.2025 |
Zostavax |
|
EU/1/06/341 |
11.4.2025 |
||
|
14.4.2025 |
Arsenic trioxide Mylan |
|
EU/1/20/1427 |
15.4.2025 |
||
|
14.4.2025 |
Regkirona |
|
EU/1/21/1597 |
16.4.2025 |
—
Issuing of a marketing authorisation (Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council; Article 5 of Regulation (EU) 2019/6 of the European Parliament and of the Council): Accepted|
Date of the decision |
Name of the medicinal product |
INN (International Non-Proprietary Name) |
Holder of the marketing authorisation |
Number of the entry in the Community Register |
Pharmaceutical form |
ATC code (Anatomical Therapeutic Chemical Code) |
Date of notification |
||
|
2.4.2025 |
Omeprazole TriviumVet |
omeprazole |
|
EU/2/25/336 |
Gastro-resistant capsule, hard |
QA02BC01 |
3.4.2025 |
||
|
23.4.2025 |
HEPIZOVAC |
Epizootic haemorrhagic disease vaccine (inactivated) |
|
EU/2/25/341 |
Suspension for injection |
QI02AA |
25.4.2025 |
||
|
23.4.2025 |
PRAZIVETIN |
Praziquantel |
|
EU/2/25/340 |
Premix for medicated feeding stuff |
QP52AA01 |
28.4.2025 |
||
|
23.4.2025 |
Prevestrus vet |
finrozole |
|
EU/2/25/338 |
Film-coated tablet |
QG03XX90 |
25.4.2025 |
||
|
25.4.2025 |
Nobilis Multriva IBm+ND+EDS |
Infectious Bronchitis, Newcastle disease and Egg Drop Syndrome virus vaccine (inactivated) |
|
EU/2/25/339 |
Emulsion for injection |
QI01AA13 |
28.4.2025 |
—
Modification of a marketing authorisation (Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council; Article 5 of Regulation (EU) 2019/6 of the European Parliament and of the Council): Accepted|
Date of the decision |
Name of the medicinal product |
Holder of the marketing authorisation |
Number of the entry in the Community Register |
Date of notification |
||
|
2.4.2025 |
Cardalis |
|
EU/2/12/142 |
7.4.2025 |
||
|
2.4.2025 |
Clevor |
|
EU/2/17/222 |
4.4.2025 |
||
|
2.4.2025 |
Coxatab |
|
EU/2/22/286 |
4.4.2025 |
||
|
2.4.2025 |
Hydrocortisone aceponate Ecuphar |
|
EU/2/18/230 |
7.4.2025 |
||
|
2.4.2025 |
Porcilis ColiClos |
|
EU/2/12/141 |
3.4.2025 |
||
|
2.4.2025 |
PREVEXXION RN+HVT+IBD |
|
EU/2/20/255 |
3.4.2025 |
||
|
2.4.2025 |
Simparica Trio |
|
EU/2/19/243 |
3.4.2025 |
||
|
10.4.2025 |
Innovax-ND-H5 |
|
EU/2/24/315 |
11.4.2025 |
||
|
14.4.2025 |
Ingelvac CircoFLEX |
|
EU/2/07/079 |
16.4.2025 |
||
|
23.4.2025 |
Eluracat |
|
EU/2/23/297 |
25.4.2025 |
||
|
23.4.2025 |
Osurnia |
|
EU/2/14/170 |
29.4.2025 |
||
|
23.4.2025 |
Quadrisol |
|
EU/2/97/005 |
28.4.2025 |
||
|
23.4.2025 |
Rheumocam |
|
EU/2/07/078 |
25.4.2025 |
||
|
23.4.2025 |
Suvaxyn PRRS MLV |
|
EU/2/17/215 |
28.4.2025 |
||
|
23.4.2025 |
Veraflox |
|
EU/2/10/107 |
25.4.2025 |
—
Withdrawal of a marketing authorisation (Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council; Article 5 of Regulation (EU) 2019/6 of the European Parliament and of the Council)|
Date of the decision |
Name of the medicinal product |
Holder of the marketing authorisation |
Number of the entry in the Community Register |
Date of notification |
||
|
10.4.2025 |
Pirsue |
|
EU/2/00/027 |
14.4.2025 |
Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:
|
European Medicines Agency |
|
Domenico Scarlattilaan 6 |
|
1083 HS Amsterdam |
|
NETHERLANDS |
(1) OJ L 136, 30.4.2004, p. 1, ELI: https://data.europa.eu/eli/reg/2004/726/oj.
(2) OJ L 4, 7.1.2019, p. 43, ELI: https://data.europa.eu/eli/reg/2019/6/oj.
ELI: http://data.europa.eu/eli/C/2025/2785/oj
ISSN 1977-091X (electronic edition)